Durect (NASDAQ: DRRX)
Durect Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Durect Company Info
DURECT Corp. focuses on advancing novel and potentially lifesaving investigational therapies derived from its Epigenetic Regulator Program. Its pipeline is called DUR-928, an endogenous sulfated oxysterol and an epigenetic regulator. The company was founded by James E. Brown and Felix Theeuwes on February 6, 1998 and is headquartered in Cupertino, CA.
News & Analysis
Is It Too Late to Buy These 3 Pharmaceutical Stocks?
Relmada Therapeutics, Neoleukin Therapeutics, and Durect were among the fastest-rising pharmaceutical stocks over the past year.
Here's Why Shares of Durect Jumped Higher Today
The biotech becomes a COVID-19 play and benefits from a competitor's failure.
These Were the 10 Best Stocks of 2019
Seven biotechs led the way.
Here's Why Shares of DURECT Plummeted Today
The biotech's midstage study of DUR-928 failed, but the drug isn't dead yet.
Here's Why DURECT Jumped Higher Today
Investors jump in ahead of a binary event.
2 Biotech Stocks That Could Double Your Money
Hardly anyone's heard of either of these drugmakers, but some analysts think they could be top performers.
Why Durect Stock Is Up Today
Investors bid up the share price after the company received some bullish praise from a Wall Street pro.
Why Durect Corporation Stock Is Spiking Today
Durect gets some much-needed cash after its partner Indivior received a positive nod for its schizophrenia drug.
Valuation
Earnings Transcripts
Durect Corp (DRRX) Q3 2020 Earnings Call Transcript
DRRX earnings call for the period ending September 30, 2020.
Durect Corp (DRRX) Q2 2020 Earnings Call Transcript
DRRX earnings call for the period ending June 30, 2020.
Durect Corp (DRRX) Q1 2020 Earnings Call Transcript
DRRX earnings call for the period ending March 31, 2020.
Durect Corp (DRRX) Q4 2019 Earnings Call Transcript
DRRX earnings call for the period ending December 31, 2019.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.